Safe abortion pills, close to home: evidence from Nigeria

In many parts of Nigeria, the nearest clinic is hours away. For women who need abortion care, that distance is not just inconvenient. It can be the difference between accessing safe care and not accessing it at all. A new study finds that women who obtained misoprostol from local medicine vendors had outcomes as safe as those who went to clinics, evidence that abortion pills don’t have to begin or end at a formal health facility. In communities where misoprostol is the only accessible option and formal care is out of reach, that finding is not just encouraging—it is essential.

Pictured above: The stall of a patent medicine vendor in Makurdi, Nigeria. © Ipas/Sophoto Studios

What is a PMV?

A patent medicine vendor is a neighborhood medicine seller, also known as a chemist, who lacks formal pharmaceutical training but is legally permitted to sell certain over-the-counter medicines. In many rural and underserved Nigerian communities, PMVs are the most accessible health resource available.

What the study found

The evidence is clear: women who obtained misoprostol from PMVs did not have worse outcomes than women who obtained it from clinics on the study’s primary measure: the need for additional treatment to complete the abortion.

Key findings

• Additional treatment was less common in the PMV group. The rate of additional treatment was 3.6% for women who obtained misoprostol from PMVs, compared with 9.5% for women who obtained it from clinics.
• No abortion-related complications were reported by participants in either group. A small proportion of women in each cohort reported visiting a health-care professional after taking misoprostol, but the study shows there were no complications reported by study participants.
• Women in both groups felt similarly prepared. 92% percent of women in both groups said they felt prepared for what would happen after taking misoprostol.
• Acceptability was high in both groups. 89% of the clinic cohort and 90% of the PMV cohort said they would recommend medication abortion to a friend.

Why these findings matter

The study looks at abortion care as women who actually access it in a restrictive setting, and not only as it is imagined in formal health systems. This research adds evidence to a pathway that already exists and that many women already use.

It also matters because in places where mifepristone is unavailable, restricted, or difficult to access, misoprostol may be the option people can actually obtain. Even where mifepristone is available, its cost can put it out of reach, making a misoprostol-alone regimen a critical alternative. For anyone working to expand safe abortion care, that’s a crucial factor to consider.

Research to drive action

These findings build on the ways women already access and navigate care. This evidence supports continued investment in self-managed abortion with pills, in pharmacy and drug-seller engagement, and in providing accurate information and quality medication outside of formal clinical settings. It also strengthens the case that expanding access and method choice in a localized way does not mean compromising safety. This is consistent with the World Health Organization’s recommendation of self-care interventions across countries and economic settings. Women do not have to choose between what is reachable and what is safe—self-managed abortion with pills can be both.